BUDESONIDE WITH FORMOTEROL

Information current as at: 1 May 2025

PBAC meeting date: July 2019
Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Symbicort® Turbuhaler® 200/6; Symbicort® Rapihaler® 100/3
Pharmaceutical company:
AstraZeneca Pty Ltd
Condition/indication:
(therapeutic use)
  • Asthma
PBAC Submission type:
New listing (Major)
Comment:
--
Related medicines:

Progress Details

Submission received for:
July 2019 PBAC meeting
Opportunity for consumer comment:
Open 01/05/2019 and close 12/06/2019 (see PBS Website)
PBAC meeting:
Held on 10/07/2019
PBAC outcome published:
Not Recommended (see PBAC Outcomes)
Lodgement of required documentation:
Not applicable
Agreement to listing arrangements:
Not applicable
Government processes:
Not applicable
Medicine listed on the PBS:
Not applicable

Case ID: a007

Page last updated: 31 October 2024

v.9.18